(fifthQuint)Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa and Prevenar in Healthy Infants.

 All participants who completed trial A3L24 (NCT01177722) will be recruited to participate in this trial.

 Those who received DTaP-IPV-Hep B-PRP-T combined vaccine will be randomized to receive either a booster dose of DTaP-IPV-Hep B-PRP-T or Infanrix hexa cent vaccine.

 Those who received Infanrix hexa cent will receive a booster dose of DTaP-IPV-Hep B-PRP-T combined vaccine.

 All participants will receive a booster dose of Prevenar cent concomitantly.

.

 Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa and Prevenar in Healthy Infants@highlight

This is a follow-up of the primary series vaccination schedule in Study A3L24 (NCT01177722).

 The objectives are: - To describe the antibody persistence to any antigen contained in the investigational DTaP-IPV-Hep B-PRP-T vaccine and Infanrix hexa cent prior to the booster dose - To describe the safety and immunogenicity of the booster dose of either DTaP-IPV-Hep B-PRP-T or Infanrix hexa cent vaccine.

 - To describe the immunogenicity of a booster dose of Prevenar cent given at 12 to 24 months.

